SCHEDULE 13G: BCLS Fund III Discloses 14.9% Stake in Heartflow

BCLS Fund III Investments, LP, a Bain Capital Life Sciences entity, has reported a 14.9% beneficial ownership stake in Heartflow, Inc., holding 12,448,158 shares of common stock.

Summary

• BCLS Fund III Investments, LP, a Delaware limited partnership, has filed a Schedule 13G disclosing beneficial ownership in Heartflow, Inc.
• As of September 30, 2025, the Reporting Person beneficially owned 12,448,158 shares of Heartflow, Inc. Common Stock.
• This ownership represents approximately 14.9% of Heartflow, Inc.'s outstanding Common Stock.
• The percentage is based on 83,396,102 shares of Common Stock outstanding as of August 31, 2025, as reported by Heartflow, Inc. in its Quarterly Report on Form 10-Q filed on September 19, 2025.
• BCLS Fund III Investments, LP, along with related Bain Capital Life Sciences entities, shares both voting and dispositive power over all 12,448,158 shares.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant passive ownership stake by an institutional investor, which is generally viewed as neutral to slightly positive as it indicates confidence from a major fund.

Positives

• A significant institutional investor, BCLS Fund III Investments, LP (part of Bain Capital Life Sciences), has disclosed a substantial 14.9% stake in Heartflow, Inc., indicating a notable level of confidence in the company's long-term prospects.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the company or the reporting person regarding future performance or strategy.

Industry Context

The disclosure of a significant stake by a specialized life sciences investment fund like Bain Capital Life Sciences in Heartflow, Inc. suggests continued institutional interest in the medical technology and diagnostics sector. Such investments can be viewed as a validation of the company's market position and potential within its industry.

Stakeholder Impact

• Shareholders may view the significant stake by a reputable institutional investor as a positive signal, potentially bolstering confidence in the company's valuation and future prospects.

Key Dates

Recommendation

The filing indicates a substantial passive investment by a reputable life sciences fund, BCLS Fund III Investments, LP, in Heartflow, Inc. While this is a disclosure of existing ownership rather than a new investment decision, the significant 14.9% stake suggests a long-term interest and confidence in the company's prospects from a sophisticated institutional investor. This generally provides a neutral to slightly positive signal, warranting a 'hold' recommendation for existing investors, as it doesn't present new fundamental performance data but confirms institutional backing.

Keywords

Heartflow Inc., BCLS Fund III Investments, Bain Capital Life Sciences, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing